Proliferation and immunohistochemistry for p53, CD25 and CK20 in predicting prognosis of non-muscle invasive papillary urothelial carcinomas

Proliferation and immunohistochemistry for p53, CD25 and CK20 in predicting prognosis of non-muscle invasive papillary urothelial carcinomas

Show other versions (1)

Bibliographic Details
Main Authors:	Vebjørn Kvikstad, Melinda Lillesand, Einar Gudlaugsson, Ok Målfrid Mangrud, Emma Rewcastle, Ivar Skaland, Jan P. A. Baak, Emiel A. M. Janssen
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2024-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10817121/?tool=EBI

Similar Items

Proliferation and immunohistochemistry for p53, CD25 and CK20 in predicting prognosis of non-muscle invasive papillary urothelial carcinomas.
by: Vebjørn Kvikstad, et al.
Published: (2024-01-01)

Mitotic activity index and CD25+ lymphocytes predict risk of stage progression in non-muscle invasive bladder cancer.
by: Melinda Lillesand, et al.
Published: (2020-01-01)

Prognostic value and reproducibility of different microscopic characteristics in the WHO grading systems for pTa and pT1 urinary bladder urothelial carcinomas
by: Vebjørn Kvikstad, et al.
Published: (2019-08-01)

Reproducibility and prognostic value of WHO1973 and WHO2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder.
by: Ok Målfrid Mangrud, et al.
Published: (2014-01-01)

Integrating Genetic Alterations and Histopathological Features for Enhanced Risk Stratification in Non-Muscle-Invasive Bladder Cancer
by: Melinda Lillesand, et al.
Published: (2024-09-01)

The Prognostic Value of the Proliferation Marker Phosphohistone H3 (PPH3) in Luminal, Basal-Like and Triple Negative Phenotype Invasive Lymph Node-Negative Breast Cancer
by: Ivar Skaland, et al.
Published: (2009-01-01)

Dual Functions of Androgen Receptor Overexpression in Triple-Negative Breast Cancer: A Complex Prognostic Marker
by: Umay Kiraz, et al.
Published: (2025-01-01)

Automatic Diagnostic Tool for Predicting Cancer Grade in Bladder Cancer Patients Using Deep Learning
by: Rune Wetteland, et al.
Published: (2021-01-01)

Validation study of MARCKSL1 as a prognostic factor in lymph node-negative breast cancer patients.
by: Nina Gran Egeland, et al.
Published: (2019-01-01)

Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.
by: Kristin Jonsdottir, et al.
Published: (2014-01-01)

Cell-cycle and Apoptosis Regulators (p16INK4A, p21CIP1, α-Catenin, Survivin, and hTERT) and Morphometry-Defined MPECs Predict Metachronous Cancer Development in Colorectal Adenoma Patients
by: Kjetil Soreide, et al.
Published: (2007-01-01)

Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers.
by: Kristin Jonsdottir, et al.
Published: (2012-01-01)

Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid
by: Alowami Salem, et al.
Published: (2008-02-01)

LOH at 1p31 (ARHI) and Proliferation in Lymph Node-Negative Breast Cancer
by: Emiel A. M. Janssen, et al.
Published: (2009-01-01)

Discrimination of grade 2 and 3 cervical intraepithelial neoplasia by means of analysis of water soluble proteins recovered from cervical biopsies
by: Skaland Ivar, et al.
Published: (2011-06-01)

Consistent condom use increases spontaneous regression in high-risk non-HPV16 but not in HPV16 CIN2-3 lesions, a prospective population-based cohort study
by: Munk Ane, et al.
Published: (2012-11-01)

CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia
by: Daniel J. Neal, et al.
Published: (2020-05-01)

Influence of pre-operative oral carbohydrate loading vs. standard fasting on tumor proliferation and clinical outcome in breast cancer patients ─ a randomized trial
by: Tone Hoel Lende, et al.
Published: (2019-11-01)

Quantitative proteomics and immunohistochemistry uncover NT5DC2 as a diagnostic biomarker for papillary urothelial carcinoma
by: Jun Yong Kim, et al.
Published: (2024-08-01)

CK20 and CK5/6 Immunohistochemical Staining of Urothelial Neoplasms: A Perspective
by: Mohammed Akhtar, et al.
Published: (2020-01-01)

Role Of TTF-1, CK20, And CK7 Immunohistochemistry for Diagnosis of Primary and Secondary Lung Adenocarcinoma
by: Yue-Chiu Su, et al.
Published: (2006-01-01)

Diagnostic Roles of Immunohistochemical Markers CK20, CD44, AMACR, and p53 in Urothelial Carcinoma In Situ
by: Daeseon Yoo, et al.
Published: (2023-09-01)

Predictive value of CK5 and CK20 for prognosis in upper urinary tract urothelial carcinoma
by: LIU Chuan, et al.
Published: (2022-05-01)

Immunohistochemical Comparison of p53 Expression, Intensity and Distribution in Different Papillary Urothelial Cancers
by: Abdolhamid Esmaeeli, et al.
Published: (2022-05-01)

Can proliferation biomarkers reliably predict recurrence in World Health Organization 2003 defined endometrial stromal sarcoma, low grade?
by: Weiwei Feng, et al.
Published: (2013-01-01)

Anti-CK7/CK20 Immunohistochemistry Did Not Associate with the Metastatic Site in TTF-1-Negative Lung Cancer
by: Alice Court, et al.
Published: (2022-06-01)

CK14 Expression Identifies a Basal/Squamous-Like Type of Papillary Non-Muscle-Invasive Upper Tract Urothelial Carcinoma
by: Minsun Jung, et al.
Published: (2020-04-01)

Comparing the Prognostic Value of PTEN and Akt Expression with the Mitotic Activity Index in Adjuvant Chemotherapy-Treated Node-Negative Breast Cancer patients aged <55 years
by: Emiel A. M. Janssen, et al.
Published: (2007-01-01)

Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer
by: Tanan Bejrananda, et al.
Published: (2021-10-01)

Diagnostic and Prognostic Roles of GATA3 Immunohistochemistry in Urothelial Carcinoma
by: Daeseon Yoo, et al.
Published: (2023-08-01)

The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver.
by: Jain, R, et al.
Published: (2010)

Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.
by: Danijel Sikic, et al.
Published: (2017-01-01)

Comparison of RNAscope and immunohistochemistry for evaluation of the UPK2 status in urothelial carcinoma tissues
by: Jiangli Lu, et al.
Published: (2022-01-01)

Immunohistochemistry‐based molecular subtypes of urothelial carcinoma derive different survival benefit from platinum chemotherapy
by: Csilla Olah, et al.
Published: (2025-01-01)

Expression of CK19 in papillary thyroid carcinoma in comparison with benign thyroid lesions
by: Thura Abbas Fadhel
Published: (2023-04-01)

Ki-67 and CK-19 are predictors of locoregional recurrence in papillary thyroid carcinoma
by: Aline de Oliveira Ribeiro Viana, et al.
Published: (2020-06-01)

Bellini Duct Carcinoma Misdiagnosed with Urothelial Papillary Carcinoma
by: Joey El Khoury, et al.
Published: (2020-01-01)

Papillary urothelial carcinoma of the ureter – A rare entity
by: Samarth Shukla, et al.
Published: (2024-07-01)

Importance of cytokeratin-20 expression in papillary urothelial neoplasia
by: İbrahim Karabulut, et al.
Published: (2020-12-01)

Carcinomas in the bladder with papillary and pseudopapillary morphology - not always urothelial
by: Daniel Abensur Athanazio, et al.
Published: (2020-11-01)